Forward Therapeutics' FT2109 advances to Phase 2 after clearing Phase 1 with once-daily oral dosing and a supportive safety ...

A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind spot in how ...

First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, ...

Jon Himoff, Chief Product Officer of Image Analysis Group (IAG), on why purpose-built imaging platforms outperform assembled ...

Symphony RCT shows 55% closure rate in diabetic foot ulcers at 12 weeks, outperforming standard care alone with faster ...

Tekton Research's St. Louis site exceeded its enrollment goal in an Alzheimer's trial despite joining mid-stream as a rescue site.

VenaSeal cyanoacrylate closure healed 88% of venous leg ulcers with 92-day median healing time in 24-month study of excluded ...

AnnJi advances AJ201 into Phase 3 trial for Kennedy's disease, targeting 200 ambulatory patients globally with a potential ...

Niia Signature Patch achieves 20-minute glucose signal recovery after insulin bolus, addressing a key challenge in all-in-one ...

DHHS 2026 Unified Agenda proposes five clinical research rule changes affecting Phase 1 INDs, single IRB requirements, and ...

Survodutide delivers 13.1% weight loss in Phase III trial for obesity and type 2 diabetes, with significant glycemic ...

Lundbeck presents baseline enrollment data from Phase III MASCOT trial of amlenetug for multiple system atrophy, with ...